HLS Therapeutics Inc (HLTRF PINK) stock market data APIs
$3.0187
0(0%)
as of April 25, 2025
HLS Therapeutics Inc Financial Data Overview
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company's lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Prev. Close
3.0187
Open
3.0187
High
3.0187
Low
3.0187
52 wk Range
2.22-3.45
Market Cap
95 544 K
Shares Outstanding
31 793 K
Revenue
56 619 K
EPS
-0.0951
Beta
1.012
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get HLS Therapeutics Inc data using free add-ons & libraries
Get HLS Therapeutics Inc Fundamental Data
HLS Therapeutics Inc Fundamental data includes:
- Net Revenue: 56 619 K
- EBITDA: 14 986 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
HLS Therapeutics Inc News
New
HLS Therapeutics Announces CFO Departure
John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson TORONTO, Dec. 18, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused ...
HLS Therapeutics (TSE:HLS) shareholders have endured a 78% loss from investing in the stock three years ago
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big losses like the plague. So spare a thought for the long term shareholders of HLS...
Some HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates
The latest analyst coverage could presage a bad day for HLS Therapeutics Inc. (TSE:HLS), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a lit...
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
